These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 19809386)
1. Testosterone concentrations in hair of hypogonadal men with and without testosterone replacement therapy. Thomson S; Koren G; Van Steen V; Rieder M; Van Uum SH Ther Drug Monit; 2009 Dec; 31(6):779-82. PubMed ID: 19809386 [TBL] [Abstract][Full Text] [Related]
2. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy. Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272 [TBL] [Abstract][Full Text] [Related]
3. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Lanfranco F; Zitzmann M; Simoni M; Nieschlag E Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966 [TBL] [Abstract][Full Text] [Related]
4. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. Rochira V; Balestrieri A; Madeo B; Granata AR; Carani C J Androl; 2006; 27(2):165-75. PubMed ID: 16278367 [TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ J Androl; 1998; 19(6):761-8. PubMed ID: 9876028 [TBL] [Abstract][Full Text] [Related]
6. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. Coward RM; Simhan J; Carson CC BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. Wang C; Harnett M; Dobs AS; Swerdloff RS J Androl; 2010; 31(5):457-65. PubMed ID: 20133964 [TBL] [Abstract][Full Text] [Related]
11. Effect of aromatizable and unaromatizable androgen replacement in hypogonadal men on GH responsiveness. Gleeson HK; Shalet SM Clin Endocrinol (Oxf); 2009 Jan; 70(1):109-15. PubMed ID: 18549466 [TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy. Gould DC; Feneley MR; Kirby RS BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134 [TBL] [Abstract][Full Text] [Related]
13. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. Burris AS; Banks SM; Carter CS; Davidson JM; Sherins RJ J Androl; 1992; 13(4):297-304. PubMed ID: 1399830 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic significance of free salivary testosterone measurement using a direct luminescence immunoassay in healthy men and in patients with disorders of androgenic status. Goncharov N; Katsya G; Dobracheva A; Nizhnik A; Kolesnikova G; Herbst V; Westermann J Aging Male; 2006 Jun; 9(2):111-22. PubMed ID: 16916746 [TBL] [Abstract][Full Text] [Related]
15. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men]. Asscheman H; Gooren LJ Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775 [TBL] [Abstract][Full Text] [Related]
16. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832 [TBL] [Abstract][Full Text] [Related]